Home | News | Events | Contact Us | English | 繁體中文 | 日本語
About Us Product & Service Facilities Quality & Compliance For Investors Career
Latest Events
Latest News
Product & Service
CPhI Japan, Tokyo, Japan
Apr. 14-16, 2021
DCAT Week, New York
Jul. 12-15, 2021
US Patent No.US10766900B2 entitled Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof was granted on Sep 8, 2020. 2020-09-30
Formosa Labs and Fresenius Kabi enter into a Registration and Distribution Agreement for a breast cancer chemotherapy injection. 2020-09-16
Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. 2020-09-15
Filed CN DMF of Gadoterate Meglumine (#Y20200000802, date of submission: Sep. 14, 2020) 2020-09-14
TW Patent No. I703163 entitled Method for preparing Sugammadex Sodium and crystalline form thereof was granted on Sep 1, 2020. 2020-09-01
Active Pharmaceutical Ingredients
Contract Development and Manufacturing Organization (CDMO)
Antibody Drug Conjugates (ADCs)
Injectable Manufacturing Services



 
Copyright ©2014 Formosa Laboratories, Inc. All Rights Reserved.
丙肝